Oral Combination Chemotherapy for Metastatic Breast Cancer
Author Information
Author(s): Yoshimoto M, Tada K, Tokudome N, Kutomi G, Tanabe M, Goto T, Nishimura S, Makita M, Kasumi F
Primary Institution: Breast Oncology Group, Cancer Institute Hospital, Tokyo, Japan
Hypothesis
Can the combination of 5′-deoxy-5-fluorouridine and cyclophosphamide improve treatment outcomes for metastatic breast cancer?
Conclusion
The oral combination chemotherapy of 5′-DFUR and CPA is effective and has low toxicity for patients with metastatic breast cancer.
Supporting Evidence
- The overall response rate was 59.6%, with a complete response rate of 17.0%.
- Patients with hormone receptor-positive tumors had higher response rates.
- The median time to progression was 11.7 months.
- The treatment was well tolerated with mild side effects.
- Patients experienced a median overall survival of 40.3 months.
Takeaway
This study tested a new way to treat breast cancer using two pills instead of injections, and it worked well with fewer side effects.
Methodology
This was an open-label Phase II trial where patients received a combination of 5′-DFUR and CPA orally for treatment.
Potential Biases
Potential bias due to the open-label design and lack of a control group.
Limitations
The study was conducted at a single institute and may not be generalizable to all populations.
Participant Demographics
{"age":{"mean":55.5,"range":"31-77"},"menopausal_status":{"pre":21,"post":79},"receptor_status":{"ER_positive":47,"ER_negative":26,"unknown":28,"PgR_positive":39,"PgR_negative":31,"PgR_unknown":30}}
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 49.0–69.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website